Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles
- PMID: 19782109
- PMCID: PMC3385993
- DOI: 10.1016/j.vaccine.2009.09.047
Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles
Abstract
As history has demonstrated, post-approval obstacles can impede a vaccine's use and potentially lead to its withdrawal. Addressing these potential obstacles when changes in a vaccine's technology can still be easily made may improve a vaccine's chances of success. Augmented vaccine target product profiles (TPPs) can help vaccine scientists better understand and anticipate these obstacles and galvanize conversations among various vaccine stakeholders (e.g., scientists, marketers, business development managers, policy makers, public health officials, health care workers, third party payors, etc.) earlier in a vaccine's development.
(c) 2009 Elsevier Ltd. All rights reserved.
References
-
- Chin Y, Lee BY. Principles and practice of clinical trial medicine. New York: Elsevier; 2008.
-
- Harrell H. Currents in contemporary ethics: HPV vaccines, privacy, and public health. J Law Med Ethics Spring. 2009;37(1):134–8. - PubMed
-
- Dowling TS. Mandating a human papillomavirus vaccine: an investigation into whether such legislation is constitutional and prudent. Am J Law Med. 2008;34(1):65–84. - PubMed
-
- Udesky L. Push to mandate HPV vaccine triggers backlash in USA. Lancet. 2007 Mar;369(9566):979–80. - PubMed
-
- Charo RA. Politics, parents, and prophylaxis—mandating HPV vaccination in the United States. N Engl J Med. 2007 May;356(19):1905–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
